Much has been discovered about the pathogenesis of myeloproliferative neoplasms, including mutations in JAK2, MPL, and TET2. The approval of ruxolitinib in 2011, a selective JAK inhibitor, underscores how an understanding of disease mechanisms can foster the development of drugs targeted to specific pathways. Using case presentations, this symposium will review dilemmas in diagnosing myelofibrosis; update the experience with JAK inhibition in primary myelofibrosis; explore the role of HDAC inhibitors and potential new combinations in myelofibrosis treatment; and examine the transplant option for these patients.

Accreditation Statement
Hemedicus, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit
Hemedicus designates this live activity for a maximum of 3 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.